OGD/R + RB: After oxygen-glucose deprivation/reoxygenation (OGD/R), cells were treated with 1 M Rhodamine B in DMEM for 24 h during the reoxygenation phase
Verma reports holding a Tier 1 Canada Research Chair in Cardiovascular Surgery and receiving grants, research support, and speaking honoraria from and acting as an advisor for Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, the Canadian Heart Research Centre, the Canadian Medical and Surgical Knowledge Translation Research Group, Eli Lilly, HLS Therapeutics, Humber River Health, Janssen, Merck, Novartis, Novo Nordisk, Pfizer, PhaseBio, S & L Solutions Event Management, Inc, Sanofi, and Sun Pharma
Fast delivery to Edinburgh, and the purity report was attached without having to ask
The role of homocysteine as a risk factor of ischemic stroke: a systematic review and meta-analysis